changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
Canada, 25 August 2016
BTG International Canada Inc. announced it received approval for its drug-eluding device, the DC Bead LUMI, from Health Canada. The bead is the first commercially available product for patients with hepatocellular carcinoma and colorectal cancer metastasized to the liver.
Read More >
Select CONTINUE to proceed to the BTG website or LEAVE to learn more at BSC.com